In this article:

PAX-101 is under clinical development by Paxmedica and currently in Phase II for Autism Spectrum Disorder (ASD). According to GlobalData, Phase II drugs for Autism Spectrum Disorder (ASD) have a 49% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PAX-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

PAX-101 overview

Suramin (PAX-101) is under development for the treatment of human African trypanosomiasis (HAT), pervasive developmental disorder (PDD, autism spectrum disorder (ASD)) and fragile X syndrome tremor-ataxia (FXTAS), long COVID-19 syndrome (LCS) and myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). It is administered through intravenous route. The drug candidate acts by targeting P2X- and P2y purinergic receptors.

Paxmedica overview

Paxmedica is an early clinical stage biopharmaceutical company. The Company is focused on the development of anti-purinergic therapies (APT) for the treatment of neurodevelopmental disorders, including autism spectrum disorder (ASD) and Fragile X syndrome tremor-ataxia (FXTAS). Its pipeline includes PAX-101 and PAX-102. It is focused on the development and testing of its lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD, FXTAS and Human African Trypanosomiasis (HAT). Its lead neurodevelopmental indication for PAX-101 is ASD. PAX-102, an intranasal formulation of suramin, is also being developed for neurodevelopmental indications.It is headquartered in Woodcliff Lake, New Jersey, United States.

For a complete picture of PAX-101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.